This pilot phase IIa trial studies how well exemestane works in treating patients with
complex atypical hyperplasia of the endometrium/endometrial intraepithelial neoplasia or low
grade endometrial cancer. Exemestane may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth.
Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma